|drug1678||Inspiratory Muscle Training Wiki||1.00|
There is one clinical trial.
In light of the corona virus pandemic (COVID-19), there is critical need to conserve scarce mechanical ventilation (MV) resources. This study evaluates an intervention in non-infected cardiac patients as a means to assist with minimizing MV and ICU length of stay (LOS). Pre-op inspiratory muscle training (IMT) has been shown to decrease pulmonary complications, MV dependence, and ICU LOS following thoracic surgery. The investigators aim to determine the mechanism of remodeling in diaphragms of adults who undergo pre-op IMT.
Description: Maximal inspiratory pressure will be quantified in cm of water pressure.Measure: Maximal inspiratory pressure Time: Post breathing exercise sessions (up to 4 weeks)
Description: Histology will be used to determine fiber type and cross-sectional area using primary antibodies for laminin and type-specific myosin heavy chain, followed by a triple immunofluorescence-conjugated secondary antibody labeling technique.Measure: Muscle fiber cross-sectional area and fiber type proportion. Time: Intra-operatively
Description: Spirometry will be used to measure peak expiratory flow during a voluntary cough maneuver. It will be quantified in liters per second.Measure: Peak expiratory flow Time: Post breathing exercise sessions (up to 4 weeks)
Description: Time to extubation will be measured as hours of post-operative mechanical ventilation.Measure: Time to extubation Time: Up to discharge from ICU
Description: Length of ICU stay will be measured as hours spent in ICU after surgery.Measure: Length of ICU stay Time: Up to 1 month
Description: Length of hospital stay will be measured as hours spent in hospital after surgery.Measure: Length of hospital stay Time: Up to 1 month
Description: Histology will be used to assess neuromuscular junction number and morphology using immunofluorescent-labeled antibodies for synaptophysin and alpha bungarotoxin. Neuromuscular junction image stacks will be visualized with confocal microscopy and morphology classified according to endplate area and area fractions of fragmented junctions, acetylcholine receptor-occupied endplate area, synaptophysin-occupied endplates, and abandoned endplates.Measure: Neuromuscular junction morphology Time: Intra-operatively
Description: RNA isolation will be performed using Tri Reagent and chloroform based manual method. RNA will be quantified and RNA-Seq will be used to assess gene expression.Measure: Muscle differential gene expression Time: Intra-operatively
Description: Physical function will be assessed with the Patient Reported Outcomes Measurement Information System Physical Function questionnaire. Each answer corresponds to a number between 1 and 5.Measure: Physical Function Time: Post breathing exercise sessions (up to 4 weeks)
Description: Dyspnoea will be assessed with the Dyspnoea 12 Questionnaire. Responses range from None to Severe.Measure: Dyspnoea Time: Post breathing exercise sessions (up to 4 weeks)
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports